ACVR1B Polyclonal Antibody, Invitrogen™
Manufacturer: Thermo Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | PIPA586391-Each-of-1 | In Stock | ₹ 46,502.50 |
PIPA586391 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 46,502.50
GST (18%): ₹ 8,370.45
Total Price: ₹ 54,872.95
Antigen
ACVR1B
Classification
Polyclonal
Conjugate
Unconjugated
Gene
ACVR1B
Gene Alias
6820432J04, activin A receptor type 1B, activin A receptor type IB, activin A receptor, type 1B, activin A receptor, type IB, activin A receptor, type II-like kinase 4, activin receptor type IB, Activin receptor type-1B, activin receptor-like kinase 4, ACTRI, ActRIB, ActR-IB, ACVR1A, Acvr1b, ACVRLK2, ACVRLK4, ALK2, Alk4, ALK-4, FOP, Serine/threonine-protein kinase receptor R2, SKR1, SKR2, TSRI
Host Species
Rabbit
Purification Method
Antigen affinity chromatography
Regulatory Status
RUO
Gene ID (Entrez)
11479, 29381, 91
Content And Storage
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Form
Liquid
Applications
Immunocytochemistry, Immunohistochemistry (Paraffin)
Concentration
1 mg/mL
Formulation
PBS with 50% glycerol and 0.02% sodium azide, pH 7.2
Gene Accession No.
P36896, P80202, Q61271
Gene Symbols
ACVR1B
Immunogen
Synthetic peptide, corresponding to amino acids 100-150 of Human ACTR-IB.
Quantity
100 μL
Primary or Secondary
Primary
Target Species
Human, Mouse, Rat
Product Type
Antibody
Isotype
IgG
Related Products
Description
- ACVR1B is a serine/threonine kinase involved in signal transduction and cellular communication
- Several truncated ACVR1B isoforms have been reported to be exclusively expressed in human pituitary tumors
- Mutations of ACVR1B have been observed in pancreatic adenocarcinomas
- Type I and II receptors form a stable complex after ligand binding, resulting in phosphorylation of type I receptors by type II receptors
- ACVR1B encodes activin A type IB receptor, composed of 11 exons
- Alternative splicing and alternative polyadenylation result in 3 fully described transcript variants
- The mRNA expression of variants 1, 2, and 3 is confirmed, and a potential fourth variant contains an alternative exon 8 and lacks exons 9 through 11, but its mRNA expression has not been confirmed.